<DOC>
	<DOC>NCT00419952</DOC>
	<brief_summary>The purpose of this study is to determine the effectiveness and safety of SYMBICORT® pMDI (a medication approved by the Food and Drug Administration, FDA) in the African American population.</brief_summary>
	<brief_title>A Comparison of SYMBICORT® pMDI With Budesonide HFA pMDI in African American Subjects With Asthma.</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Male or Female, African American (selfreported), ≥12 years of age Moderate to severe asthma requiring treatment with an inhaled corticosteroid Diagnosis of asthma for at least 6 months Subjects requiring treatment with systemic corticosteroids (e.g., oral, parenteral, ocular) Any significant disease or disorder that may jeopardize a subject's safety</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Moderate Asthma</keyword>
	<keyword>Severe Asthma</keyword>
</DOC>